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Neuroprotection aims to prevent neuronal 
injury, ideally with preservation of function. 
Many neurological disorders, including 
ischemic, traumatic, or degenerative insults, 
share common features of destruction of 
neurons mediated by similar pathophysiological 
mechanisms including apoptosis (programmed 
cell death), increased release of excitotoxic amino 
acids, (particularly glutamate), intracellular 
accumulation of calcium, oxidative stress by 
radical oxygen species, and inflammatory 
reactions accompanied by infiltration of cells and 
production of cytokines. It has been shown that 
neurons, like many other cells, have the potential 
to regenerate. The concept of pharmacologic 
neuroprotection is directed at halting or 
possibly reversing general mechanisms of cell 
death, especially apoptosis, and restoring or 
regenerating cell function rather than treating 
specific disease entities. 
Erythropoietin (EPO), a 30.4 kilo Dalton 
glycoprotein hormone, promotes red blood 
cell differentiation by preventing apoptosis 
of erythroid progenitors in the bone marrow. 
In recent years, erythropoietin has been 
shown to possess potent neuroprotective and 
neuroregenerative properties. This agent has 
been shown to reduce retinal ganglion cell 
apoptosis in vitro, a finding which was later 
corroborated by in vivo studies. Retinal ganglion 
cell survival in animal models was promoted 
by erythropoietin after optic nerve transection, 
chronically elevated intraocular pressure and 
diabetic retinopathy. 
Recently, promising results have been 
reported using systemic and intravitreal 
erythropoietin for different ocular conditions. 
Kashkouli et al evaluated the effect of 
intravenous erythropoietin for treatment of 
indirect traumatic optic neuropathy (TON) and 
compared the outcomes of such treatment with 
no specific intervention. Mean best-corrected 
visual acuity (BCVA) significantly (P=0.028) 
improved from 1.82 logMAR at baseline to 
0.94 logMAR at final follow-up in the EPO 
group, whereas the observation group showed 
insignificant (P=0.28) visual improvement from 
2.55 logMAR to 2.32 logMAR. Li et al determined 
the effect of intravitreal erythropoietin in 5 eyes 
with severe, chronic diabetic macular edema 
unresponsive to prior multi-modal treatment. 
They reported that visual acuity improved by 
3 lines or more in 3 eyes and by 1 line in 2 
eyes. Visual improvement occurred within a 
week after initial intravitreal EPO injection and 
was maintained up to 18 weeks. Modarres et 
al reported the results of intravitreal injection 
of erythropoietin in eyes with non-arteritic 
anterior ischemic optic neuropathy. After the 
injections, 64.5% and 54.8% of eyes experienced 
3 or more lines of improvement in visual acuity 
at 3 months and at final follow-up, respectively. 
Their results were distinctly superior to the 
natural course of the disease (39.5% rate of 
improvement of 3 lines or more after 3 months 
according to the Ischemic Optic Neuropathy 
Decompression Trial). 
Neuroprotection is an evolving strategy 
for limiting or possibly reversing neuronal/
axonal injury due to a variety of insults. 
This concept may be used as a therapeutic 
option in glaucoma, vascular occlusions, 
or retinal degenerative disorders. Further 
studies are required to elucidate the potential 
benefits of erythropoietin in different ocular   
conditions.News
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